[HTML][HTML] Programmed cell death-ligand 2: new insights in cancer
Y Yang, X Yan, X Bai, J Yang, J Song - Frontiers in Immunology, 2024 - frontiersin.org
Immunotherapy has revolutionized cancer treatment, with the anti-PD-1/PD-L1 axis therapy
demonstrating significant clinical efficacy across various tumor types. However, it should be …
demonstrating significant clinical efficacy across various tumor types. However, it should be …
[HTML][HTML] In Search of Better Peptide-(Derived from PD-L2)-Based Immune Checkpoint Inhibitors
B Klebansky, M Backer, V Gorbatyuk, O Vinogradova… - Biomolecules, 2024 - mdpi.com
Current anti-cancer immune checkpoint therapy relies on antibodies that primarily target the
PD-1/PD-L1 (-L2) negative regulatory pathway. Although very successful in some cases for …
PD-1/PD-L1 (-L2) negative regulatory pathway. Although very successful in some cases for …
Prostate-specific membrane antigen cars and methods of use thereof
Y Zhao, SHS Lin, X Liu, A Chew - US Patent 11,992,503, 2024 - Google Patents
The present disclosure provides modified immune cells (eg, modified T cells) comprising a
chimeric antigen receptor (CAR) having affinity for a prostate-specific membrane antigen …
chimeric antigen receptor (CAR) having affinity for a prostate-specific membrane antigen …